A new trial update was recorded on August 4, 2026, for a study involving gonadorelin-class agent ZOLADEX. The trial, registered as NCT07310420, is titled "A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer." It is listed as a Phase 1 study. Its current status is recruiting. The trial focuses on premenopausal women with hormone receptor positive, HER2 negative advanced breast cancer. No results have been posted for this trial at this stage. The study record does not state efficacy outcomes, safety findings, or conclusions. This brief reflects only the status and design details listed in the trial registration as of the update date. Readers interested in the study details, eligibility criteria, or enrollment progress can consult the official trial registry entry directly. For general background on gonadorelin and its approved regulatory status, readers can refer to the compound overview.
Phase 1 Trial of Gonadorelin-Related Zoladex Now Recruiting
See the full gonadorelin overview
Source: https://clinicaltrials.gov/study/NCT07310420